Clinical trials: Post-ERCP Acute Pancreatitis.
Post-ERCP Acute Pancreatitis
Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP Prevention
Patients undergoing endoscopic retrograde cholangiopancreatography (ERCP) are at risk for post-ERCP pancreatitis (PEP), which is associated with adverse outcomes.
- Trial name
- NCT04425993
- Testing
- Isosorbide Dinitrate 5 MG, Indomethacin 100 MG
- Where
- 4 sites in China
- Volunteers
- 2,700 people
- Sponsor
- Air Force Military Medical University, China
Post-ERCP Acute Pancreatitis
Short-term Intravenous Fluids for Prevention of Post-ERCP Pancreatitis
This study will explore the efficacies of several practical short-term (peri-procedural) intravenous fluid regimens in the prevention of post- endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP).
- Trial name
- STRIPE (NCT06260878)
- Testing
- Intravenous Ringer's lactate
- Where
- Canada
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- University of Calgary
Acute Pancreatitis (AP), Gallstone Pancreatitis
Pentoxifylline Treatment in Acute Pancreatitis (AP)
The purpose of this study was to determine the effects (good and bad) of giving a drug called pentoxifylline to patients with acute pancreatitis.
- Conditions
- Acute Pancreatitis (AP), Gallstone Pancreatitis, Alcoholic Pancreatitis, Trauma Acute Pancreatitis
- Trial name
- AP (NCT02487225)
- Testing
- Pentoxifylline
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Mayo Clinic
Pancreatitis, Acute
COX-2 Inhibitor to Prevent Post-ERCP Pancreatitis
Acute pancreatitis is the most common and feared complication of ERCP, occurring after 1% to 30% of procedures. Since 2012, a multicenter RCT was published in NEJM, indomethacin use in high risk patients was considered a…
- Trial name
- NCT02964403
- Testing
- Cox-2, Indomethacin
- Volunteers
- 2,700 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University